Signifor Related Clinical Trials
Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers [Completed]
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. [Recruiting]
Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma [Recruiting]
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess [Completed]
A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer [Recruiting]
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer [Terminated]
Pasireotide LAR in Severe Polycystic Liver Disease [Recruiting]
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) [Active, not recruiting]
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues [Recruiting]
Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size [Active, not recruiting]
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease [Recruiting]
Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas [Terminated]
Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma [Terminated]
Pasireotide in Prevention of GI Toxicity [Recruiting]
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease [Recruiting]
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function [Completed]
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET [Completed]
Monthly SOM230C for Recurrent or Progressive Meningioma [Active, not recruiting]
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors [Completed]
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease [Completed]
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma [Completed]
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors [Active, not recruiting]
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Active, not recruiting]
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer [Completed]
3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial [Active, not recruiting]
Efficacy and Safety of Pasireotide LAR in Japanese Patients With Acromegaly or Pituitary Gigantism [Active, not recruiting]
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly [Active, not recruiting]
Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping Syndrome [Completed]
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer [Recruiting]
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease [Completed]
Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs [Completed]
A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma [Active, not recruiting]
IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus [Withdrawn]
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly [Recruiting]
Phase I Trial of Combination of FOLFIRI and SOM 230 [Active, not recruiting]
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor [Recruiting]
Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma [Recruiting]
Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Hepatic Cysts [Recruiting]
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease [Recruiting]
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease [Recruiting]
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma [Withdrawn]
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma [Active, not recruiting]
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease [Completed]
Pasireotide Therapy in Patients With Nelson's Syndrome [Terminated]
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases [Active, not recruiting]
Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer [Recruiting]
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly [Active, not recruiting]
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients [Completed]
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) [Active, not recruiting]
Expression Profile of Somatostatin Receptors and Dopamine Receptor 2 in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vivo Response to Pasireotide and Cabergoline [Recruiting]
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly [Approved for marketing]
Intra-patient Dose Escalation Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide (SOM230) Subcutaneous (s.c.) Followed by Pasireotide LAR in Patients With Dumping Syndrome [Active, not recruiting]
Treatment of Hypoglycemia Following Gastric Bypass Surgery [Not yet recruiting]
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial [Completed]
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin [Active, not recruiting]
Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease [Completed]
A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers [Completed]
Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs [Active, not recruiting]
A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease [Completed]
Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer [Recruiting]
|